Clinical-stage immunology company INmune Bio is stepping up efforts to reprogram the innate immune system for cancer and neurodegenerative disease treatment through the development and commercialization of product candidates. Its programs include the ovarian cancer solid tumor targeting INKmune, high-risk myelodysplastic syndrome treatment, INB03, as well as XPro1595 aiming to treat Alzheimer's disease and treatment-resistant depression. INmune Bio also holds license agreements with Xencor, Immune Ventures, and the University of Pittsburgh. The Florida-based company was founded in 2015.
INmune Bio's ticker is INMB
The company's shares trade on the NASDAQ stock exchange
They are based in La Jolla, California
There are 1-10 employees working at INmune Bio
It is inmunebio.com
INmune Bio is in the Healthcare sector
INmune Bio is in the Biotechnology industry
The following five companies are INmune Bio's industry peers: